Cite
HARVARD Citation
Imbimbo, M. et al. (n.d.). 125P A phase IIa study of the novel immunogenic cell death (ICD) inducer PT-112 plus avelumab ("PAVE") in advanced non-small cell lung cancer (NSCLC) patients (pts). Immuno-oncology technology. p. . [Online].